Diabetic Foot Ulcer Biologics Global Market Report 2025
상품코드:1810881
리서치사:The Business Research Company
발행일:On Demand Report
페이지 정보:영문 250 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
당뇨병성 족부궤양 생물학적 제제 시장 규모는 향후 몇 년 동안 강력한 성장이 예상됩니다. 2029년에는 CAGR 8.3%로 26억 5,000만 달러로 성장할 것입니다. 예측 기간의 성장은 재생의료에 대한 자금 지원 증가, 치료 지연을 경험하는 노인 인구의 증가, 광범위한 상환 프로그램에 대한 접근성, 생물학적 치료에 초점을 맞춘 임상시험의 증가, 사지 보존 치료에 대한 관심의 증가와 관련이 있습니다. 이 기간 동안 주요 동향으로는 생물학적 상처 치유 기술의 발전, 줄기세포 치료의 기술 혁신, 조직공학적인 피부 대체재 개발, 세포외 매트릭스 제품의 발전, 만성 상처 관리에 있어 3D 바이오프린팅 응용의 부상 등을 들 수 있습니다.
당뇨병 유병률의 증가는 향후 몇 년 동안 당뇨병성 족부궤양 생물학적 제제 시장의 성장을 견인할 것으로 예상됩니다. 당뇨병은 체내에서 인슐린을 생성하거나 적절히 사용하지 못해 혈당치가 상승하는 만성질환입니다. 당뇨병 환자의 증가는 주로 앉아서 생활하는 생활습관에 기인하며, 일상 생활에 지장을 최소화하면서 혈당을 효과적으로 관리할 수 있는 케어 솔루션에 대한 요구가 증가하고 있습니다. 당뇨병성 족부궤양 생물학적 제제는 상처 치유 촉진, 감염 예방, 만성 족부궤양과 관련된 합병증 감소 등 당뇨병 관리에 중요한 역할을 하고 있습니다. 예를 들어, 2025년 4월 벨기에에 본부를 둔 비영리 단체인 국제당뇨병연맹(IDF) 아틀라스는 2024년 성인 당뇨병 환자 5억 8,900만 명 중 9억 5,500만 명이 1형 당뇨병 환자이며, 2050년에는 8억 5,300만 명으로 늘어날 것으로 예측했습니다. 이처럼 당뇨병 유병률의 증가는 당뇨병성 족부궤양 생물학적 제제 시장의 성장을 촉진하고 있습니다.
당뇨병성 족부궤양 생물학적 제제 시장의 주요 기업들은 태반 유래 동종 이식편과 같은 생물학적 치료법의 발전에 집중하여 상처 치유를 개선하고 합병증을 최소화하며 만성 족부궤양 환자의 치료 결과를 개선하는 데 주력하고 있습니다. 태반 유래 동종 이식편은 양막, 융모 등 인간 태반 조직에서 제공된 생체 조직 이식편으로 치유를 촉진하고 염증을 억제하며 조직 재생을 돕습니다. 예를 들어, 2025년 1월 미국 제약회사 바이오스템 테크놀러지스(Biostem Technologies)는 당뇨병성 족부궤양 치료를 위해 벤다제와 함께 바이오리테인 기술을 이용한 임상시험을 시작했습니다. 이 임상시험은 완치되지 않은 당뇨병성 족부궤양 치료에 있어 벤다제와 표준치료제를 병용한 경우와 표준치료제만 병용한 경우의 치료 효과를 비교합니다. 또한, 치유된 상처의 장기적인 내구성과 안정성을 평가하는 후속 단계도 포함되며, 치료의 지속적인 성공과 궤양 재발 위험 감소를 목표로 합니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세, 그리고 코로나와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계의 당뇨병성 족부궤양 생물학적 제제 : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
최종 이용 산업 분석
세계의 당뇨병성 족부궤양 생물학적 제제 시장 : 성장률 분석
세계의 당뇨병성 족부궤양 생물학적 제제 시장 실적 : 규모와 성장, 2019-2024
세계의 당뇨병성 족부궤양 생물학적 제제 시장 예측 : 규모와 성장, 2024-2029, 2034F
세계의 당뇨병성 족부궤양 생물학적 제제 : 총 잠재 시장 규모(TAM)
제6장 시장 세분화
세계의 당뇨병성 족부궤양 생물학적 제제 시장 : 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
성장인자
피부 대체품
콜라겐 기반 생물학적 제제
세포 기반 생물학적 제제
세계의 당뇨병성 족부궤양 생물학적 제제 시장 : 적응증별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
신경허혈성 궤양
신경장애성 당뇨병성 족부궤양
허혈성 당뇨병성 족부궤양
세계의 당뇨병성 족부궤양 생물학적 제제 시장 : 기술별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
유전자 치료
줄기세포 치료
조직공학
세계의 당뇨병성 족부궤양 생물학적 제제 시장 : 최종사용자별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
병원
클리닉
외래 수술 센터
장기간병 시설
기타 최종사용자
세계의 당뇨병성 족부궤양 생물학적 제제 시장 : 하위 세분화 성장인자(종류별), 실적과 예측, 2019-2024, 2024-2029F, 2034F
혈소판 유래 성장인자
상피성장인자
섬유아세포 증식인자
혈관내피 세포 증식인자
세계의 당뇨병성 족부궤양 생물학적 제제 시장 : 하위 세분화 피부 대체품(종류별), 실적과 예측, 2019-2024, 2024-2029F, 2034F
합성 피부 대체품
생물학적 피부 대체품
복합 피부 대체품
세계의 당뇨병성 족부궤양 생물학적 제제 시장 : 하위 세분화 콜라겐 기반 생물학적 제제(종류별), 실적과 예측, 2019-2024, 2024-2029F, 2034F
소 유래 콜라겐
돼지 유래 콜라겐
인간 유래 콜라겐
세계의 당뇨병성 족부궤양 생물학적 제제 시장 : 하위 세분화 세포 유래 생물학적 제제(종류별), 실적과 예측, 2019-2024, 2024-2029F, 2034F
자가 세포 기반 생물학적 제제
동종 세포 기반 생물학적 제제
줄기세포 기반 생물학적 제제
제7장 지역별·국가별 분석
세계의 당뇨병성 족부궤양 생물학적 제제 시장 : 지역별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
세계의 당뇨병성 족부궤양 생물학적 제제 시장 : 국가별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 개요
당뇨병성 족부궤양 생물학적 제제 시장 : 경쟁 구도
당뇨병성 족부궤양 생물학적 제제 시장 : 기업 개요
Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
Zimmer Biomet Holdings Inc. Overview, Products and Services, Strategy and Financial Analysis
Smith & Nephew plc Overview, Products and Services, Strategy and Financial Analysis
Integra LifeSciences Holdings Corp. Overview, Products and Services, Strategy and Financial Analysis
Gunze Ltd. Overview, Products and Services, Strategy and Financial Analysis
제31장 기타 주요 기업과 혁신적 기업
Organogenesis Holdings Inc.
MIMEDX Group Inc.
LifeNet Health
Bharat Biotech
BioTissue Holdings Inc.
Aroa Biosurgery
Tissue Regenix Group plc
Stempeutics Research
Energenesis Biomedical Co. Ltd.
Human Biosciences Inc.
Helixmith Co. Ltd.
ACell Inc.
Anterogen Co. Ltd.
Lavior Pharma Inc.
Technophage SA
제32장 세계의 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병
제34장 최근의 시장 동향
제35장 시장 잠재력이 높은 국가, 부문, 전략
당뇨병성 족부궤양 생물학적 제제 시장 2029 : 새로운 기회를 제공하는 국가
당뇨병성 족부궤양 생물학적 제제 시장 2029 : 새로운 기회를 제공하는 부문
당뇨병성 족부궤양 생물학적 제제 시장 2029 : 성장 전략
시장 동향에 기반한 전략
경쟁 전략
제36장 부록
KSM
영문 목차
영문목차
Diabetic foot ulcer biologics consist of advanced therapeutic products made from living cells, tissues, or biological materials that aid in wound healing and tissue regeneration for diabetic foot ulcers. These biologics support the body's natural repair mechanisms by supplying critical growth factors, extracellular matrices, and cellular elements that speed up healing and lower the risk of complications from chronic diabetic wounds.
The primary categories of diabetic foot ulcer biologics include growth factors, skin substitutes, collagen-based biologics, and cell-based biologics. Growth factors are natural or synthetic agents that encourage cell growth, differentiation, and tissue regeneration to facilitate healing. Common indications for these biologics include neuro-ischemic ulcers, neuropathic diabetic foot ulcers, and ischemic diabetic foot ulcers. Technologies involved encompass gene therapy, stem cell therapy, and tissue engineering. These products are utilized by various end users such as hospitals, clinics, ambulatory surgical centers, long-term care facilities, and more.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.
The diabetic foot ulcer biologics market research report is one of a series of new reports from The Business Research Company that provides diabetic foot ulcer biologics market statistics, including the diabetic foot ulcer biologics industry global market size, regional shares, competitors with the diabetic foot ulcer biologics market share, detailed diabetic foot ulcer biologics market segments, market trends, and opportunities, and any further data you may need to thrive in the diabetic foot ulcer biologics industry. This diabetic foot ulcer biologics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The diabetic foot ulcer biologics market size has grown strongly in recent years. It will grow from $1.78 billion in 2024 to $1.93 billion in 2025 at a compound annual growth rate (CAGR) of 8.5%. The growth during the historic period was driven by the rising number of diabetic patients, an increase in chronic wound cases, heightened demand for advanced wound care solutions, expansion of healthcare facilities, and greater clinical recognition of biologic therapies.
The diabetic foot ulcer biologics market size is expected to see strong growth in the next few years. It will grow to $2.65 billion in 2029 at a compound annual growth rate (CAGR) of 8.3%. The forecast period's growth can be linked to increased funding in regenerative medicine, a growing elderly population experiencing delayed healing, broader access to reimbursement programs, more clinical trials focused on biologic treatments, and heightened attention to limb preservation therapies. Key trends during this time include progress in biologic wound healing technologies, ongoing innovations in stem cell therapies, creation of tissue-engineered skin substitutes, advancements in extracellular matrix products, and the rise of 3D bioprinting applications in chronic wound management.
The growing prevalence of diabetes is anticipated to drive the expansion of the diabetic foot ulcer biologics market in the coming years. Diabetes is a chronic condition marked by elevated blood sugar levels due to the body's inability to produce or properly use insulin. The increase in diabetes cases is largely attributed to sedentary lifestyles, which create a greater need for long-term care solutions that effectively manage blood glucose while minimizing daily life disruption. Diabetic foot ulcer biologics play a crucial role in diabetes management by accelerating wound healing, preventing infections, and reducing complications related to chronic foot ulcers. For example, in April 2025, the International Diabetes Federation (IDF) Atlas, a Belgium-based non-profit organization, reported that in 2024, 9.5 million of the 589 million adults with diabetes had type 1 diabetes, with projections estimating this number to rise to 853 million by 2050. Thus, the increasing diabetes prevalence is fueling the growth of the diabetic foot ulcer biologics market.
Leading companies in the diabetic foot ulcer biologics market are concentrating on advancing biologic therapies such as placental-derived allografts to improve wound healing, minimize complications, and enhance patient outcomes for chronic foot ulcer treatment. Placental-derived allografts consist of biological tissue grafts sourced from donated human placental tissues like the amnion or chorion, which promote healing, decrease inflammation, and support tissue regeneration. For instance, in January 2025, BioStem Technologies Inc., a US-based pharmaceutical company, initiated a clinical trial using its BioREtain technology alongside Vendaje for diabetic foot ulcer treatment. The study compares the efficacy of Vendaje combined with standard care versus standard care alone in healing non-healing diabetic foot ulcers. It also includes a follow-up phase to assess the long-term durability and stability of healed wounds, aiming to ensure lasting treatment success and lower the risk of ulcer recurrence.
In March 2022, Convatec Group plc, a UK-based medical products and technologies company, acquired Triad Life Sciences Inc. for an undisclosed amount. This acquisition allows Convatec to enhance its advanced wound care portfolio by incorporating Triad Life Sciences' innovative porcine placental tissue biologics, expanding treatment options for difficult-to-heal wounds such as diabetic foot ulcers. Triad Life Sciences Inc. is a US-based manufacturer specializing in biologically derived products for diabetic foot ulcer care.
Major players in the diabetic foot ulcer biologics market are Johnson & Johnson, Zimmer Biomet Holdings Inc., Smith & Nephew plc, Integra LifeSciences Holdings Corp., Gunze Ltd., Organogenesis Holdings Inc., MIMEDX Group Inc., LifeNet Health, Bharat Biotech, BioTissue Holdings Inc., Aroa Biosurgery, Tissue Regenix Group plc, Stempeutics Research, Energenesis Biomedical Co. Ltd., Human Biosciences Inc., Helixmith Co. Ltd., ACell Inc., Anterogen Co. Ltd., Lavior Pharma Inc., Technophage SA.
North America was the largest region in the diabetic foot ulcer biologics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in diabetic foot ulcer biologics report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the diabetic foot ulcer biologics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The diabetic foot ulcer biologics market consists of revenues earned by entities by providing services such as wound care management services, personalized treatment planning, post-operative care and follow-up, telemedicine and remote monitoring, and clinical trial and research services. The market value includes the value of related goods sold by the service provider or included within the service offering. The diabetic foot ulcer biologics market also includes sales of bioreactors and cell culture systems, tissue processing and preservation devices, wound dressing application tools, and automated cell sorting and separation machines. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Diabetic Foot Ulcer Biologics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on diabetic foot ulcer biologics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for diabetic foot ulcer biologics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The diabetic foot ulcer biologics market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
3. Diabetic Foot Ulcer Biologics Market Trends And Strategies
4. Diabetic Foot Ulcer Biologics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
5. Global Diabetic Foot Ulcer Biologics Growth Analysis And Strategic Analysis Framework
5.1. Global Diabetic Foot Ulcer Biologics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Diabetic Foot Ulcer Biologics Market Growth Rate Analysis
5.4. Global Diabetic Foot Ulcer Biologics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Diabetic Foot Ulcer Biologics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Diabetic Foot Ulcer Biologics Total Addressable Market (TAM)
